ZNTL on Nasdaq

Zentalis Pharmaceuticals, Inc.

Pharmaceutical preparations company, listed on Nasdaq (ZNTL).

Price unavailable

Last updated Oct 18, 2026.

Overview

Compare with Kura Oncology, Rockwell Medical Inc. or ENANTA PHARMACEUTICALS INC, or pick any stock.

TickerZNTL on Nasdaq
IndustryPharmaceutical Preparations
Business address10275 Science Center Drive, Suite 200, San Diego, Ca 92121²
Filer categoryNon-accelerated filer, Smaller reporting company²

See how the biggest companies compare on our leaderboards

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2025

-100.0%Revenue growth, 2025³

-63.4%Return on equity³

-$125.2MFree cash flow³

Financial statements

Revenue⁴³$0 in 2025

Operating income⁵⁶⁷⁴³-$152.8M in 2025+226% since 2019

Net income⁵⁶⁷⁴³-$137.1M in 2025+200% since 2019

Every line of the income statement as filed: the last 3 fiscal years, latest first.³

Period ending	2025-12-31	2024-12-31	2023-12-31
Revenues from Licensing and Sales of Intellectual Property	$0	$67.4M	$0
Research and development	$107.3M	$167.8M	$189.6M
Zentera in-process research and development	$0	$0	$45.6M
General and administrative	$37.7M	$87.1M	$64.4M
Restructuring	$7.8M	$0	$0
Goodwill impairment	$0	$3.7M	$0
Total operating expenses	$152.8M	$258.6M	$299.5M
Loss from operations	-$152.8M	-$191.2M	-$299.5M
Investment and other income, net	$16.2M	$25.5M	$22.6M
Net loss before income taxes	-$136.6M	-$165.7M	-$276.9M
Income tax expense (benefit)	$442.0K	$177.0K	-$601.0K
Loss on equity method investment	$0	$0	$16.0M
Net loss	-$137.1M	-$165.9M	-$292.3M
Net loss attributable to noncontrolling interests	$0	-$28.0K	-$114.0K
Net loss attributable to Zentalis	-$137.1M	-$165.8M	-$292.2M
Net loss per common share outstanding, basic (in dollars per share)	-$1.91	-$2.33	-$4.47
Net loss per common share outstanding, diluted (in dollars per share)	-$1.91	-$2.33	-$4.47
Common shares used in computing net loss per share, basic (in shares)	71.9M shares	71.1M shares	65.4M shares
Common shares used in computing net loss per share, diluted (in shares)	71.9M shares	71.1M shares	65.4M shares

Total assets¹⁰⁵⁶⁷⁴³$289.0M in 2025+230% since 2019

Total liabilities¹⁰⁵⁶⁷⁴³$72.8M in 2025+282% since 2019

Shareholders’ equity⁶⁷⁴³$216.2M in 2025

Cash⁵⁶⁷⁴³$36.0M in 2025−46% since 2019

Every line of the balance sheet as filed: the last 3 fiscal years (annual) or 3 quarters (quarterly), latest first.³

Period ending	2025-12-31	2024-12-31	2023-12-31
Cash and cash equivalents	$36.0M	$33.9M	$28.0M
Marketable debt securities, available for sale	$209.9M	$318.0M
Marketable equity securities	$0	$19.2M
Contracts receivable	$0	$5.0M
Prepaid expenses and other current assets	$7.3M	$10.0M
Total current assets	$253.2M	$386.1M
Property and equipment, net	$2.8M	$4.7M
Operating lease right-of-use assets	$26.3M	$32.5M
Prepaid expenses and other assets	$4.1M	$4.4M
Restricted cash	$2.6M	$2.6M	$2.7M
Total assets	$289.0M	$430.3M
Accounts payable	$7.2M	$7.4M
Accrued expenses	$29.4M	$45.3M
Total current liabilities	$36.6M	$52.7M
Long-term lease liability	$35.7M	$39.6M
Other long-term liabilities	$500.0K	$849.0K
Total liabilities	$72.8M	$93.2M
Preferred stock, $0.001 par value; 10,000,000 shares authorized, no shares issued and outstanding at December 31, 2025 and 2024	$0	$0
Common stock, $0.001 par value; 250,000,000 shares authorized; 69,085,980 and 71,282,400 shares issued and outstanding at December 31, 2025 and 2024, respectively	$69.0K	$71.0K
Additional paid-in capital	$1.4B	$1.4B
Accumulated other comprehensive income	$196.0K	$558.0K
Accumulated deficit	-$1.2B	-$1.1B
Total stockholders' equity	$216.2M	$337.2M
Total liabilities and stockholders' equity	$289.0M	$430.3M
Preferred stock, par value (in dollars per share)	$0.00	$0.00
Preferred stock, shares authorized (in shares)	10.0M shares	10.0M shares
Preferred stock, shares issued (in shares)	0 shares	0 shares
Preferred stock, shares outstanding (in shares)	0 shares	0 shares
Common stock, par value (in dollars per share)	$0.00	$0.00
Common stock, shares authorized (in shares)	250.0M shares	250.0M shares
Common stock, shares issued (in shares)	69.1M shares	71.3M shares
Common stock, shares outstanding (in shares)	69.1M shares	71.3M shares

Period ending	2025-12-31	2024-12-31	2023-12-31
Cash and cash equivalents	$36.0M	$33.9M	$28.0M
Marketable debt securities, available for sale	$209.9M	$318.0M
Marketable equity securities	$0	$19.2M
Contracts receivable	$0	$5.0M
Prepaid expenses and other current assets	$7.3M	$10.0M
Total current assets	$253.2M	$386.1M
Property and equipment, net	$2.8M	$4.7M
Operating lease right-of-use assets	$26.3M	$32.5M
Prepaid expenses and other assets	$4.1M	$4.4M
Restricted cash	$2.6M	$2.6M	$2.7M
Total assets	$289.0M	$430.3M
Accounts payable	$7.2M	$7.4M
Accrued expenses	$29.4M	$45.3M
Total current liabilities	$36.6M	$52.7M
Long-term lease liability	$35.7M	$39.6M
Other long-term liabilities	$500.0K	$849.0K
Total liabilities	$72.8M	$93.2M
Preferred stock, $0.001 par value; 10,000,000 shares authorized, no shares issued and outstanding at December 31, 2025 and 2024	$0	$0
Common stock, $0.001 par value; 250,000,000 shares authorized; 69,085,980 and 71,282,400 shares issued and outstanding at December 31, 2025 and 2024, respectively	$69.0K	$71.0K
Additional paid-in capital	$1.4B	$1.4B
Accumulated other comprehensive income	$196.0K	$558.0K
Accumulated deficit	-$1.2B	-$1.1B
Total stockholders' equity	$216.2M	$337.2M
Total liabilities and stockholders' equity	$289.0M	$430.3M
Preferred stock, par value (in dollars per share)	$0.00	$0.00
Preferred stock, shares authorized (in shares)	10.0M shares	10.0M shares
Preferred stock, shares issued (in shares)	0 shares	0 shares
Preferred stock, shares outstanding (in shares)	0 shares	0 shares
Common stock, par value (in dollars per share)	$0.00	$0.00
Common stock, shares authorized (in shares)	250.0M shares	250.0M shares
Common stock, shares issued (in shares)	69.1M shares	71.3M shares
Common stock, shares outstanding (in shares)	69.1M shares	71.3M shares

Cash from operations⁵⁶⁷⁴³-$125.2M in 2025+220% since 2019

Capital spending⁵⁶⁷⁴³$0 in 2025

Free cash flow⁵⁶⁷⁴³-$125.2M in 2025+217% since 2019

Share buybacks³$10.0M in 2025

Every line of the cash flow as filed: the last 3 fiscal years, latest first.³

Period ending	2025-12-31	2024-12-31	2023-12-31
Net loss	-$137.1M	-$165.9M	-$292.3M
Depreciation and amortization	$739.0K	$1.3M	$1.4M
Operating lease right-of-use and fixed asset impairment	$4.1M	$0	$5.0M
Noncash consideration portion of Zentera in-process research and development	$0	$0	$15.0M
Share-based compensation	$20.7M	$67.3M	$54.8M
Goodwill impairment	$0	$3.7M	$0
(Gain)/loss on disposal of equipment	-$660.0K	-$13.0K	$406.0K
Non-cash impact of revenues from licensing and sales of intellectual property	$0	-$47.4M	$0
Non-cash recognized mark-to-market of equity securities	-$1.2M	-$5.2M	$0
Accretion of discounts on marketable securities, net	-$2.8M	-$8.0M	-$13.2M
Loss on equity method investment	$0	$0	$16.0M
Deferred income taxes	$0	$0	-$853.0K
Deconsolidation of Kalyra	$0	-$79.0K	$0
Accounts receivable	$5.0M	-$5.0M	$0
Prepaid expenses and other assets	$3.0M	$6.2M	-$5.7M
Accounts payable and accrued liabilities	-$17.3M	-$18.0M	$10.9M
Operating lease right-of-use assets and liabilities, net	$201.0K	$264.0K	$623.0K
Net cash used in operating activities	-$125.2M	-$170.9M	-$207.8M
Purchases of marketable debt securities	-$139.5M	-$128.0M	-$549.2M
Proceeds from maturities of marketable debt securities	$250.0M	$271.2M	$505.3M
Proceeds from sale of marketable equity securities	$20.4M	$33.5M	$0
Proceeds from sale of property and equipment	$698.0K	$65.0K	$0
Purchases of property and equipment	$0	-$221.0K	-$583.0K
Net cash provided by (used in) investing activities	$131.6M	$176.6M	-$44.5M
Proceeds from issuance of common stock, net	$5.4M	$0	$235.7M
Proceeds from issuance of common stock under equity incentive plans	$304.0K	$349.0K	$1.6M
Repurchase of common stock	-$10.0M	$0	$0
Net-settlement of restricted stock unit vesting	$0	-$241.0K	$0
Net cash (used in) provided by financing activities	-$4.3M	$108.0K	$237.3M
Net increase (decrease) in cash, cash equivalents and restricted cash	$2.1M	$5.8M	-$15.0M
Income taxes paid	$85.0K	$359.0K	$140.0K
Right-of-use assets obtained in exchange for operating lease liabilities	$0	$0	$602.0K

Compare Zentalis Pharmaceuticals, Inc. with another company

Leadership

Who has led Zentalis Pharmaceuticals, Inc., and when. Pick a name to see everywhere that person has worked.

Chief executive

President

Chief financial officer

Chief operating officer

2025

Chief executive officerJulia Marie Eastland Nov 13, 2024 to now¹¹
Chief executive officerKimberly Blackwell May 20, 2022 to Feb 5, 2024¹²
PresidentJulia Marie Eastland Nov 13, 2024 to now¹¹
PresidentKimberly Blackwell May 20, 2022 to May 20, 2022¹²
PresidentCam Gallagher May 31, 2022 to May 31, 2024¹³
Chief financial officerCam Gallagher May 31, 2024 to May 31, 2024¹⁴
Chief financial officerMelissa B. Epperly Apr 3, 2020 to Feb 12, 2024¹⁵
Chief operating officerIris Roth Feb 13, 2023 to Mar 2, 2023¹⁶
Chief operating officerKevin D. Bunker Apr 3, 2020 to Aug 12, 2022¹⁷

Board members and other officers (21)

Chief Scientific OfficerMark Lackner Jan 3, 2024 to Feb 5, 2025¹⁸
Chief Medical OfficerDiana Hausman Feb 5, 2024 to May 9, 2024¹⁹
Principal Accounting OfficerVincent Vultaggio Apr 11, 2024 to now²⁰
Chief Medical OfficerIngmar Bruns Nov 13, 2024 to now²¹
Chief Medical OfficerCarrie Brownstein Oct 3, 2022 to Oct 6, 2023²²
Chief Scientific OfficerKevin D. Bunker Oct 3, 2022 to Dec 21, 2023²³
SVP, Clinical DevelopmentDimitris Voliotis Apr 3, 2020 to Feb 14, 2022²⁴
Board memberShannon Campbell May 27, 2026 to now²⁵
Board memberLuke Nathaniel Walker May 29, 2024 to now²⁶
Board memberJulia Marie Eastland Nov 13, 2024 to now¹¹
Board memberScott Dunseth Myers Nov 13, 2024 to now²⁷
Board memberDiana Hausman May 10, 2023 to May 10, 2023²⁸
Board memberJan Skvarka Sep 12, 2022 to now²⁹
Board memberEnoch Kariuki Feb 10, 2021 to now³⁰
Board memberCam Gallagher Apr 3, 2020 to May 31, 2024³¹
Board memberDavid E. Goel Apr 3, 2020 to Apr 3, 2020³²
Board memberKaran S. Takhar Apr 3, 2020 to Apr 3, 2020³³
Board memberKimberly Blackwell Jul 1, 2020 to Feb 5, 2024³⁴
General counselJames B. Bucher Sep 22, 2025 to now³⁵
General counselAndrea Paul Aug 1, 2022 to Feb 5, 2025³⁶
General counselAlexis Pinto Sep 1, 2020 to Feb 14, 2022³⁷

Former names

Zentalis Pharmaceuticals, LLCJan 8, 2020 to Apr 6, 2020²
Zeno Pharma, LLCDec 19, 2017 to Sep 5, 2019²

Timeline

Nov 13, 2024New chief executive Julia Marie Eastland becomes CEO¹¹
May 20, 2022New chief executive Kimberly Blackwell becomes CEO¹²

Filings

383 filings to the SEC since October 2021: 6 annual reports, 15 quarterly reports, 76 major events, 162 insider forms, 59 large holders, 65 other. The latest 20:

Oct 1, 20264 EDGAR
Aug 19, 2026SCHEDULE 13G/A EDGAR
Aug 19, 20264 EDGAR
Aug 14, 20268-K EDGAR
Aug 14, 2026424B5 EDGAR
Aug 13, 2026424B5 EDGAR
Aug 13, 2026SCHEDULE 13G/A EDGAR
Aug 6, 202610-Q EDGAR
Aug 6, 20268-K EDGAR
Jul 30, 2026SCHEDULE 13G EDGAR
Jun 18, 20264 EDGAR
Jun 18, 20264 EDGAR
Jun 18, 20264 EDGAR
Jun 18, 20268-K EDGAR
Jun 18, 20264 EDGAR
Jun 18, 20264 EDGAR
May 27, 20264 EDGAR
May 27, 20263 EDGAR
May 27, 2026DEFA14A EDGAR
May 27, 20268-K EDGAR

The 383 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last three years, summarized. The full record is on SEC EDGAR.

Insider trades and holders

Large holders

Investors who own more than 5% must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively. 59 such filings since October 2021, the latest 10:

From Forms 4 and Schedules 13D and 13G filed with the SEC.

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 100. Change is in shares since the quarter before.

Fund	Shares	Value	Share of the fund	Change
5AM Venture Management, LLC	3,947,913	$19.1M	6.7%	No change
BlackRock, Inc.	3,753,525	$18.2M	0.0%	+2,483,688
Squadron Capital Management LLC	3,700,000	$17.9M	6.1%	+69,000
Two Sigma Investments, LP	3,024,936	$14.7M	0.0%	+68,410
Vanguard Capital Management LLC	2,835,669	$13.8M	0.0%	+524,962
Citadel Advisors LLC	2,298,403	$11.1M	0.0%	+566,320
Renaissance Technologies LLC	1,609,078	$7.8M	0.0%	−329,067
Opaleye Management Inc.	1,412,656	$6.9M	0.6%	No change
Orbimed Advisors LLC	1,390,576	$6.7M	0.1%	New
Decheng Capital LLC	1,323,327	$6.4M	0.9%	No change
Geode Capital Management, LLC	1,284,117	$6.2M	0.0%	+663,081
Bank Of America Corp /de/	1,114,650	$5.4M	0.0%	−17,644
Ishara Investments LP	1,025,000	$5.0M	3.7%	−205,000
Primecap Management Co/ca/	957,420	$4.6M	0.0%	No change
Soleus Capital Management, L.P.	950,000	$4.6M	0.2%	New
State Street Corp	887,416	$4.3M	0.0%	+637,726
Vanguard Portfolio Management LLC	808,548	$3.9M	0.0%	+447,948
Pfizer Inc	953,834	$3.9M	2.3%	No change
Connor, Clark & Lunn Investment Management Ltd.	758,033	$3.7M	0.0%	−33,968
Millennium Management LLC	664,281	$3.2M	0.0%	−625,541
ADAR1 Capital Management, LLC	652,750	$3.2M	0.1%	+508,114
Marshall Wace, Llp	591,473	$2.9M	0.0%	+198,830
Qube Research & Technologies Ltd	574,806	$2.8M	0.0%	−62,310
D. E. Shaw & Co., Inc.	546,566	$2.7M	0.0%	−937,532
Dimensional Fund Advisors LP	542,852	$2.6M	0.0%	+270,818

13F reports cover disclosed long positions in U.S. stocks only.

Sources

The numbers on this page point here. Each one links to the record it came from.

1
SEC EDGARZentalis Pharmaceuticals, Inc. filings on SEC EDGAR
2
SEC EDGARZentalis Pharmaceuticals, Inc. filings on SEC EDGAR
3
SEC EDGARZentalis Pharmaceuticals, Inc. 10-K for fiscal 2025
4
SEC EDGARZentalis Pharmaceuticals, Inc. 10-K for fiscal 2022
5
SEC EDGARZentalis Pharmaceuticals, Inc. 10-K for fiscal 2019
6
SEC EDGARZentalis Pharmaceuticals, Inc. 10-K for fiscal 2020
7
SEC EDGARZentalis Pharmaceuticals, Inc. 10-K for fiscal 2021
8
SEC EDGARZentalis Pharmaceuticals, Inc. 10-Q for fiscal 2026
9
SEC EDGARZentalis Pharmaceuticals, Inc. 10-Q for fiscal 2026
10
SEC EDGARZentalis Pharmaceuticals, Inc. 10-K for fiscal 2019
11
SEC EDGARJulia Marie Eastland, Chief executive officer
12
SEC EDGARKimberly Blackwell, Chief executive officer
13
SEC EDGARCam Gallagher, President
14
SEC EDGARCam Gallagher, Chief financial officer
15
SEC EDGARMelissa B. Epperly, Chief financial officer
16
SEC EDGARIris Roth, Chief operating officer
17
SEC EDGARKevin D. Bunker, Chief operating officer
18
SEC EDGARMark Lackner, Chief Scientific Officer
19
SEC EDGARDiana Hausman, Chief Medical Officer
20
SEC EDGARVincent Vultaggio, Principal Accounting Officer
21
SEC EDGARIngmar Bruns, Chief Medical Officer
22
SEC EDGARCarrie Brownstein, Chief Medical Officer
23
SEC EDGARKevin D. Bunker, Chief Scientific Officer
24
SEC EDGARDimitris Voliotis, SVP, Clinical Development
25
SEC EDGARShannon Campbell, Board member
26
SEC EDGARLuke Nathaniel Walker, Board member
27
SEC EDGARScott Dunseth Myers, Board member
28
SEC EDGARDiana Hausman, Board member
29
SEC EDGARJan Skvarka, Board member
30
SEC EDGAREnoch Kariuki, Board member
31
SEC EDGARCam Gallagher, Board member
32
SEC EDGARDavid E. Goel, Board member
33
SEC EDGARKaran S. Takhar, Board member
34
SEC EDGARKimberly Blackwell, Board member
35
SEC EDGARJames B. Bucher, General counsel
36
SEC EDGARAndrea Paul, General counsel
37
SEC EDGARAlexis Pinto, General counsel